Skip to content

Very Early Medical Abortion

Very Early Medical Abortion - a Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03989869
Acronym
VEMASCOT
Enrollment
39
Registered
2019-06-18
Start date
2019-09-04
Completion date
2023-06-20
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion Early

Brief summary

The research question begin addressed by this study is Is Very Early Medical Abortion (VEMA - before a pregnancy is visible on ultrasound scan) as effective as medical abortion when performed later and an intrauterine pregnancy can be visualised with ultrasound?. This is important to patients and public, because delays to abortion care can cause mental distress, and pain and bleeding are worse at later gestations. The study is examining whether earlier or delayed administration of abortion medications affects the efficacy and side effects of the medical abortion process, in women with very early pregnancies. Any women who had a positive pregnancy test, requesting abortion, but did not have a visible pregnancy on ultrasound scan could take part in the study. Women with signs, symptoms or ultrasound findings suggesting ectopic pregnancy would not be included. This study will be conducted at a community sexual and reproductive health centre that provides abortion care. The participants will be involved in the study for a maximum period of 4 weeks. They will be randomly allocated to either immediate abortion care or delayed abortion care. In each arm of the study they will receive clinical care that they would otherwise routinely receive. In addition to this, they will receive a telephone call follow up with a short questionnaire to complete over the phone. This study is being conducted in Scotland but the results will be combined with findings from similar research groups across Europe as part of a consortium of researchers. This consortium is coordinated by the Karolinska Institutet in Sweden under the EuDRACT ID: 2018-003675-35

Interventions

Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy

Sponsors

Karolinska Institutet
CollaboratorOTHER
University of Edinburgh
CollaboratorOTHER
NHS Lothian
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Women 18 years old or above opting for medical abortion with a pregnancy estimated by gynaecological history and Last Menstrual Period (LMP - if known) to be less than 6 weeks 2. No signs of ectopic pregnancy, miscarriage or other pathological pregnancy 3. Transvaginal ultrasound (part of the clinical protocol at the abortion visit) shows no confirmed Intrauterine Pregnancy (IUP see definitions below) 4. Willing and able to return to the clinic for possible delayed treatment and at 1 to 2 weeks after the start of treatment for follow up 5. Capable of giving their informed consent to participate.

Exclusion criteria

1. Women with visible (confirmed) IUP 2. Women with contraindications to medical abortion including diagnosed pathological pregnancy at the initial examination. 3. Inability to give informed consent. The following definitions will be used according to the consensus statement on nomenclature, definitions and outcomes in pregnancy of unknown location (Barnhart et al, Fertil Steril. 2011;95:857-66): 1. Confirmed IUP: Ultrasound shows an intrauterine yolk sac or fetal structure with or without cardiac echo. 2. Not confirmed IUP: This group includes cases where: 1. ultrasound shows an empty uterine cavity (frequently referred to as PUL: Pregnancy of Unknown Location) or 2. ultrasound shows a gestational sac, or sac like structure, but without a yolk sac.

Design outcomes

Primary

MeasureTime frameDescription
Complete Abortion Rate (efficacy)Within 30 days of treatment initiationRate of complete abortion without surgical intervention, as reported by patients using a self-administered low-sensitivity pregnancy test at 2 weeks after treatment. This will be collected via telephone questionnaire.

Secondary

MeasureTime frameDescription
Complication RateWithin 30 days of treatment initiationRate of complications including ectopic pregnancy, infection.
Duration of post-abortion bleedingWithin 30 days of treatment initiationNumber of days bleeding following treatment
Acceptability of methodWithin 30 days of treatment initiationPreference for delay or immediate treatment
Visual Analogue Pain scoreWithin 30 days of treatment initiationVisual Analogue Scale of pain experienced during abortion. Mean will be reported and range of scale from 0-10.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026